.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
McKinsey
Merck
Boehringer Ingelheim
Cerilliant
Novartis
Mallinckrodt
Queensland Health
Federal Trade Commission

Generated: July 25, 2017

DrugPatentWatch Database Preview

ERAXIS Drug Profile

« Back to Dashboard

What is the patent landscape for Eraxis, and when can generic versions of Eraxis launch?

Eraxis is a drug marketed by Vicuron and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-four patent family members in twenty-nine countries.

The generic ingredient in ERAXIS is anidulafungin. One supplier is listed for this compound. Additional details are available on the anidulafungin profile page.

Summary for Tradename: ERAXIS

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list20
Clinical Trials: see list11
Patent Applications: see list979
Drug Prices:see details
DailyMed Link:ERAXIS at DailyMed

Pharmacology for Tradename: ERAXIS

Ingredient-typeLipopeptides
Drug ClassEchinocandin Antifungal
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-001Feb 17, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-002Nov 14, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-001Feb 17, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-001Feb 17, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-002Nov 14, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ERAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-001Feb 17, 2006► Subscribe► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-002Nov 14, 2006► Subscribe► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-002Nov 14, 2006► Subscribe► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-001Feb 17, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ERAXIS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,932,543 Cyclic peptide antifungal agents and process for preparation thereof► Subscribe
6,743,777 Cyclic peptide antifungal agents and process for preparation thereof► Subscribe
7,790,744Cyclic peptide antifungal agents and process for preparation thereof► Subscribe
6,916,784 Cyclic peptide antifungal agents and process for preparation thereof► Subscribe
6,384,013 Cyclic peptide antifungal agents and process for preparation thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ERAXIS

Country Document Number Estimated Expiration
Japan4936595► Subscribe
European Patent Office1582204► Subscribe
Czech Republic9300416► Subscribe
Germany69331922► Subscribe
Japan3520071► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ERAXIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008 00017Denmark► Subscribe
C/GB08/016United Kingdom► SubscribePRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920
406Luxembourg► Subscribe91406, EXPIRES: 20180318
00334Netherlands► SubscribePRODUCT NAME: ANIDULAFUNGIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
0561639/01Switzerland► SubscribePRODUCT NAME: ANIDULAFUNGIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58325 03.09.2009
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Healthtrust
Cerilliant
Deloitte
McKesson
UBS
Queensland Health
Citi
Chinese Patent Office
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot